SCHEDULE: Glazer Capital Discloses 5.84% Stake in Y-mAbs

Glazer Capital and Paul J. Glazer have reported a beneficial ownership of 5.84% in Y-mAbs Therapeutics, Inc., totaling 2,654,700 shares of common stock.

Summary

• Glazer Capital, LLC and Paul J. Glazer are the reporting persons.
• They collectively beneficially own 2,654,700 shares of Y-mAbs Therapeutics, Inc. Common Stock.
• This ownership represents 5.84% of the company's outstanding common stock.
• Both reporting persons hold shared voting power and shared dispositive power over all 2,654,700 shares.
• The shares were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's operational performance or future prospects.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investor's position in a biotechnology company, which is a common occurrence in the sector as investors seek opportunities in emerging or established pharmaceutical firms.

Stakeholder Impact

• Indicates a significant institutional investor's confidence or strategic interest in Y-mAbs Therapeutics, Inc., potentially signaling a positive view to other investors.

Key Dates

Keywords

Y-mAbs Therapeutics, Glazer Capital, Paul J. Glazer, Schedule 13G, beneficial ownership, common stock, investment, biotechnology, pharmaceutical